BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38587388)

  • 1. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
    Crawford J; Herndon D; Gmitter K; Weiss J
    Future Oncol; 2024 Apr; ():. PubMed ID: 38587388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
    Balducci L; Falandry C; List A
    Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
    Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
    Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers.
    Epstein RS; Weerasinghe RK; Parrish AS; Krenitsky J; Sanborn RE; Salimi T
    J Med Econ; 2022; 25(1):108-118. PubMed ID: 34927520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
    Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
    J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving Outcomes of Chemotherapy: Established and Novel Options for Myeloprotection in the COVID-19 Era.
    Lyman GH; Kuderer NM; Aapro M
    Front Oncol; 2021; 11():697908. PubMed ID: 34307165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
    Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
    J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.
    Epstein RS; Aapro MS; Basu Roy UK; Salimi T; Krenitsky J; Leone-Perkins ML; Girman C; Schlusser C; Crawford J
    Adv Ther; 2020 Aug; 37(8):3606-3618. PubMed ID: 32642965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
    Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
    Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
    Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
    Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
    Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
    Drews RE
    Clin Chest Med; 2003 Dec; 24(4):607-22. PubMed ID: 14710693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
    Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
    Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials.
    Qiu J; Sheng D; Lin F; Jiang P; Shi N
    Front Pharmacol; 2023; 14():1157251. PubMed ID: 37305548
    [No Abstract]   [Full Text] [Related]  

  • 15. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
    Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
    Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
    Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-medicare study.
    Epstein RS; Nelms J; Moran D; Girman C; Huang H; Chioda M
    Cancer Treat Res Commun; 2022; 31():100555. PubMed ID: 35421820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices.
    Hart L; Ogbonnaya A; Boykin K; Deyoung K; Bailey R; Heritage T; Lopez-Gonzalez L; Huang H; Gordan L
    Cancer Med; 2023 Apr; 12(8):10020-10030. PubMed ID: 37000119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing hematologic toxicities: novel therapies.
    Nirenberg A
    Cancer Nurs; 2003 Dec; 26(6 Suppl):32S-37S. PubMed ID: 15025411
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.